Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company
23.7.2024 15:00:00 EEST | Business Wire | Press release
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced that it has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed contract extends through 2029 with a notable amendment that outlines a purchase commitment for two therapeutic products representing an incremental value of approximately $250 million through the end of the renewed term.
In addition, KBI, in late June, completed a successful regulatory inspection by the U.S. Food and Drug Administration (FDA) of its mammalian operation in Durham, North Carolina. This regulatory inspection enables the company’s North Carolina operations to begin providing a mammalian drug substance commercially to one of its key strategic customers. It also demonstrates KBI’s ability to act as a preferred partner for large volume commercial therapeutic manufacturing.
“As KBI continues fulfilling its commitment to our customers in helping solve their complex manufacturing challenges, this commercial contract extension allows us to demonstrate our approach as a next-generation CDMO,” said J.D. Mowery, President and CEO of KBI Biopharma. “With this agreement as well as our successful FDA regulatory inspection, we’re driving breakthroughs in biopharmaceutical development and manufacturing that help bring new therapies to market.”
He concluded, “By establishing these trusted, long-term partnerships with global pharmaceutical leaders, we’re able to positively impact the lives of patients worldwide.”
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. With each of its 500+ customer partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global customers with six locations in Europe and the USA. More information is available at www.kbibiopharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723243720/en/
Contacts
KBI Biopharma, Inc. Company Inquiries
Sarah Wakefield
KBI Biopharma, Inc.
swakefield@kbibiopharma.com
KBI Biopharma, Inc. Media Inquiries
Kelly Biele
CG Life
kbiele@cglife.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Povofortay ® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa16.11.2026 23:30:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Povofortay® (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa (HS). “The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease,” 2,3 said Bill Meury, Chief Executive Officer, Incyte."As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.” The approval is based on results from the pivotal STOP-HS1 (NCT05620823) and STOP-HS2 (NCT05620836) trials evaluating the safety and efficacy of Povofortay in patients with moderate to severe HS.2 Data from the Phase 3 STOP-HS program demonstrated Povofortay’s clinically meaningful and
Moody’s Names Timothy Bhatt as Chief Information Officer16.11.2026 23:00:00 EET | Press release
Moody’s Corporation (NYSE: MCO) announced today that it has named Tim Bhatt to the newly created role of Chief Information Officer (CIO), effective December 7th, and that he will join the company’s Executive Leadership Team. Mr. Bhatt, who has served as Chief Technology Officer (CTO) of Moody’s Ratings since 2018, will also continue in that role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116893391/en/ Timothy Bhatt, Chief Information Officer, Moody's As CIO, Mr. Bhatt will lead Moody’s enterprise technology strategy, AI enablement, and information security, with responsibility for the company’s technology services and operations and cybersecurity teams. He will further modernize how Moody’s operates, bringing together human expertise, trusted data and AI agents to reimagine enterprise workflows and move AI agents from pilots into everyday work. Mr. Bhatt will also continue as Chief Technology Officer of Moody’s Ratin
Lattice Extends Space Heritage with On-Orbit Milestone in TESAT Optical Communication Terminals16.11.2026 23:00:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that its low power, radiation-resilient Lattice Nexus™ FPGAs have surpassed one year of on-orbit operation in TESAT optical communication terminals. Since launch, the FPGAs have delivered consistent performance in the demanding application of space-based laser communication at 10 Gbps, adding to Lattice’s space heritage of thousands of FPGAs launched to date. TESAT has flown optical communication terminals on GEO and LEO missions for more than a decade, supplying broadband constellations and institutional programs. For the redesign of its terminal electronics, Lattice Nexus FPGAs addressed TESAT’s requirements for radiation tolerance, low power, and board footprint. Built on 28 nm fully depleted silicon-on-insulator (FD-SOI) process technology, the Nexus platform is well suited to a terminal that must run for years without maintenance. “As optical links and onboard processing
New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 19:00:00 EET | Press release
Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an audience of over 300 million players, the survey shows an engaged audience with established spending habits: 84% of respondents call themselves gam
IQM Supports NVIDIA’s Work to Make Quantum Computers Schedulable in Slurm16.11.2026 18:00:00 EET | Press release
IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced at SC26 in Chicago its support for NVIDIA’s investment in making quantum processing units (QPUs) a schedulable resource in the Slurm workload manager by integrating IQM quantum computers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116814640/en/ NVIDIA is making quantum computers a schedulable resource in Slurm by integrating IQM quantum computers. NVIDIA, which has committed to keeping Slurm open source and vendor neutral, announced that Slurm 26.11 adds plugin support for Hierarchical Resources (HRES), allowing a supercomputing center to describe a QPU as a shared, cluster-level resource and connect it to external services, such as the software that manages the device. Until now, quantum computers have not fit the scheduling models Slurm uses for CPUs and GPUs, so integrations have often been built separately f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom